Trigger Protein Lipid Nanoparticles for Tumor-Targeted Drug Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current liposome-based drug delivery systems face challenges in achieving targeted and controlled release of drugs, particularly in tumor environments, where they are rapidly recognized by phagocytic cells and have limited stability in the gastrointestinal tract, leading to short circulation times and inefficient accumulation in tumors.
Innovation Solution
Development of nanoparticles with a lipid layer and a compartment surrounded by the lipid layer, where the first lipid is covalently attached to a hydrophilic polymer via a disulfide bond, and includes a trigger protein that is cleaved by enzymes like gelatinase or ADAM family proteases, allowing for controlled release in specific environments such as tumors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If conventional liposomes are used for drug delivery, then they can carry therapeutic agents, but they are rapidly recognized by phagocytic cells and have short circulation times
Solution Approach 1:
The patent modifies the liposome surface properties by incorporating trigger proteins with specific amino acid sequences that are resistant to phagocytic cell recognition. This changes the surface parameter to reduce opsonization and extend circulation time while maintaining drug delivery capability
Solution Approach 2:
The trigger protein acts as an intermediary element between the liposome and the tumor microenvironment. It provides stability in the bloodstream while being specifically activated by tumor enzymes, serving as a bridge that maintains circulation until tumor-specific conditions trigger drug release
2Productivity
If conventional liposomes are used, then they can deliver drugs to tumors, but they lack controlled release and accumulate inefficiently in tumors
Solution Approach 1:
The liposome system transitions from a static delivery vehicle to a dynamic one that responds to tumor microenvironment conditions. The trigger protein remains stable in circulation but becomes activated by tumor enzymes, dynamically controlling drug release only when needed at the tumor site
Solution Approach 2:
The trigger protein provides different properties in different locations: stability in the bloodstream and activation in the tumor microenvironment. This local differentiation enables selective tumor accumulation and controlled release only at the tumor site, improving productivity while maintaining ease of operation through passive targeting
3Object-affected harmful factors
If conventional liposomes are used, then they can provide drug delivery, but they cause severe side effects and lack targeted release
Solution Approach 1:
The trigger protein serves as a protective intermediary that prevents premature drug release in healthy tissues while enabling targeted delivery to tumors. It maintains liposome integrity in the bloodstream and only activates upon encountering tumor-specific enzymes, thereby reducing toxicity while providing adaptability for targeted release
Solution Approach 2:
The trigger protein acts as a disposable protective layer that is consumed or activated at the tumor site. Once it triggers drug release, it is no longer needed, similar to a disposable protective barrier that protects during circulation but activates only when needed, reducing overall toxicity while maintaining targeted capability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The nanoparticles demonstrate stable circulation in the bloodstream, targeted release in tumor environments, and effective delivery of therapeutic agents, such as gemcitabine, with reduced toxicity and enhanced tumor growth inhibition.
Implementation Method 1
The disulfide bond of the first lipid is stable under conditions that include 10% human serum and is broken under conditions that include 50 micromolar glutathione
Implementation Method 2
a trigger protein that is cleaved by enzymes like gelatinase or ADAM family proteases, allowing for controlled release in specific environments such as tumors
Data Source
AI summary
Provided herein are nanoparticles that include a lipid layer and a compartment surrounded by the lipid layer. The lipid layer may include a lipid and a lipoprotein. The lipid may include a POPE lipid covalently attached to a hydrophilic polymer by a disulfide bond. The lipoprotein may include a trigger protein. The concentration of the first lipid may be between 1 mol % and 30 mol %. The disulfide bond of the first lipid is stable under conditions that include 10% human serum and is broken under conditions that include 50 micromolar glutathione. The hydrophilic polymer may include a PEG molecule. The trigger protein may include an amino acid repeat region, such as (GPX)n. The trigger protein may include a peptide bond that is cleaved by a gelatinase (e.g., gelatinase-B protease), or a member of the ADAM family of proteases (e.g., ADAM10 protease). Also provided are methods of using the nanoparticles.